阿普米司特对银屑病关节炎患者附着点炎和指趾炎的疗效:PALACE 1-3 研究汇总分析
该汇总分析纳入 PALACE 1、2、3 研究中基线有附着点炎(n=945)或指趾炎(n=633)的银屑病关节炎患者,评估阿普米司特对附着点炎和指趾炎的疗效。第24周时,阿普米司特 30 mg 每日两次组附着点炎和指趾炎的平均变化显著优于安慰剂,MASES 平均和中位百分比变化也显著更优;指趾炎计数的平均和中位百分比变化在两种剂量下数值上但未显著优于安慰剂。持续用药患者中两种表现的改善维持至156周。
要点
- 第24周阿普米司特30mg每日两次组附着点炎平均变化-1.3 vs 安慰剂-0.9(p<0.05)。
- 第24周阿普米司特30mg每日两次组指趾炎平均变化-1.8 vs 安慰剂-1.3(p<0.01)。
- 指趾炎计数的平均和中位百分比变化在两种阿普米司特剂量下数值上但未显著优于安慰剂。
核心结论
- 阿普米司特对活动性银屑病关节炎有效,包括附着点炎和指趾炎的改善,持续至3年。
研究设计与样本
- PALACE 1、2、3 研究数据汇总分析,纳入基线有附着点炎(n=945)或指趾炎(n=633)的患者,接受双盲安慰剂、阿普米司特30mg每日两次或20mg每日两次治疗至52周,并继续至5年,数据分析至156周。
主要发现
- 第24周,阿普米司特30mg每日两次组附着点炎平均变化-1.3 vs 安慰剂-0.9(p<0.05)。
- 第24周,阿普米司特30mg每日两次组指趾炎平均变化-1.8 vs 安慰剂-1.3(p<0.01)。
- 第24周,阿普米司特30mg每日两次组MASES平均百分比变化-23.6% vs 安慰剂-7.0%(p<0.05),中位百分比变化-50.0% vs 安慰剂-21.1%(p<0.05)。
- 指趾炎计数的平均和中位百分比变化在两种阿普米司特剂量下数值上但未显著优于安慰剂。
- 继续使用阿普米司特的患者中,两种表现的观察平均和中位改善维持至156周。
关键数值与推荐
- 附着点炎采用马斯特里赫特强直性脊柱炎附着点炎评分(MASES)评估,指趾炎采用指趾炎计数评估。
- 第24周阿普米司特30mg每日两次组MASES平均百分比变化-23.6% vs 安慰剂-7.0%(p<0.05),中位百分比变化-50.0% vs 安慰剂-21.1%(p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features of PsA leading to disability and affecting quality of life. PALACE 1, 2 and 3 data were pooled to assess the efficacy of apremilast on enthesitis and dactylitis outcomes in patients with these conditions at baseline. METHODS: Patients with enthesitis (n=945) or dactylitis (n=633) at baseline were analysed after receiving double-blind treatment with placebo, apremilast 30 mg two times per day or apremilast 20 mg two times per day up to 52 weeks and continuing up to 5 years. Data were analysed through 156 weeks. Enthesitis was evaluated by Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and dactylitis via dactylitis count. RESULTS: At week 24, patients receiving apremilast 30 mg two times per day demonstrated a significantly greater mean change in enthesitis (-1.3 vs -0.9; p<0.05) and dactylitis (-1.8 vs -1.3; p<0.01) vs placebo. Patients in the 30 mg dose group showed significantly greater mean (-23.6% vs -7.0%; p<0.05) and median (-50.0% vs -21.1%; p<0.05) per cent changes in MASES; mean and median per cent changes in dactylitis count were numerically, but not significantly, different for either apremilast dose in patients with dactylitis. In the patient population remaining on apremilast, observed mean and median improvements in both conditions were sustained through 156 weeks. CONCLUSION: Apremilast is effective for the treatment of active PsA, including improvements in enthesitis and dactylitis up to 3 years. TRIAL REGISTRATION NUMBERS: NCT01172938, NCT01212757 and NCT01212770.
引用
- Gladman DD, Kavanaugh A, Gómez-Reino JJ, et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018. PMID: 30018799. doi:10.1136/rmdopen-2018-000669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。